Apparatuses and methods for determining a patient's response to multiple cancer drugs
Inventors
Gupta, Vaijayanti • Sen, Manimala • Sankaran, Satish • Subramanian, Kalyanasundaram • Hariharan, Ramesh • Veeramachaneni, Vamsi • Katragadda, Shanmukh • Gupta, Rohit • Bettadapura, Radhakrishna • Janakiraman, Anand • Ghosh, Arunabha • Agrawal, Smita • Srinivasan, Sujaya • Singh, Bhupender • Bahadur, Urvashi • Krishna, Shuba • Nagarajan, Mahesh • Gupta, Nimisha • BORGONHA, Sudhir
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10734117-B2
Publication Date
2020-08-04
Expiration Date
Abstract
Apparatuses (including devices and systems) and methods for determining if a patient will respond to a variety of cancer drugs.
Core Innovation
The invention provides a method of estimating a patient’s response to a plurality of cancer drugs or therapies using a marker processing apparatus. The method enters patient-specific marker values identified by testing a patient sample for a plurality of markers, and determines an equivalence level for at least some patient-specific marker values relative to reference marker values in a library of reference marker values by applying a set of equivalence rules. The equivalence level includes high equivalence, medium equivalence, low equivalence or no equivalence.
After determining equivalence, the method determines patient-specific marker values that are likely benign from those having no equivalence to a reference marker value by applying structural rules to patient-specific marker values having no equivalence. The structural rules identify a structural defect in a marker referenced by the patient-specific marker value. The method also automatically prioritizes patient-specific marker values having equivalence to the reference marker, including high equivalence, medium equivalence or low equivalence.
Based on the equivalence level patient-specific marker values, the method identifies drugs or therapies related to markers corresponding to patient-specific marker values having equivalence to a reference marker value. Finally, the method outputs an estimated response to the identified drug or therapy based on the determined equivalence level patient-specific marker values. The workflow is described as an end-to-end personalized cancer diagnostics workflow implemented as interconnected software systems that include processing, tracking, reporting, and interpretation.
The workflow incorporates data provenance and versioning across external biological sources, automated consistency tests with override and audit trail, and automated integration and export to downstream interpretation, including standardized and full actionable reporting.
Claims Coverage
Independent claim clm-00001 covers estimating a patient’s response to a plurality of cancer drugs or therapies by entering patient-specific marker values, determining equivalence levels versus reference marker values using equivalence rules, applying structural rules to classify patient-specific marker values with no equivalence and identify structural defects, prioritizing equivalent markers, and identifying drugs or therapies and outputting an estimated response based on the equivalence level. The claim therefore includes four main inventive feature groups: equivalence-level determination, structural-rule-based likely-benign identification, automatic prioritization of equivalent markers, and drug or therapy identification with response output.
Equivalence level determination from reference marker library
Determining an equivalence level for at least some of the patient-specific marker values relative to reference marker values in a library of reference marker values by applying a set of equivalence rules, wherein the equivalence level includes high equivalence, medium equivalence, low equivalence or no equivalence.
Structural rules for no-equivalence marker defect identification
Determining patient-specific marker values that are likely benign from those having no equivalence to a reference marker value by applying structural rules to the patient specific marker values having no equivalence to the reference marker value to identify a structural defect in a marker referenced by the patient specific marker value.
Automatic prioritization of equivalent patient-specific markers
Automatically prioritizing patient-specific marker values having equivalence to the reference marker, wherein the equivalence is high equivalence, medium equivalence or low equivalence.
Drug or therapy identification from equivalent markers and response output
Identifying drugs or therapies related to markers corresponding to patient-specific marker values having equivalence to a reference marker value; and outputting an estimated response to the identified drug or therapy based on the determined equivalence level patient-specific marker values.
The claim coverage centers on processing patient-specific marker values against a reference library via equivalence rules that output high, medium, low, or no equivalence, applying structural rules to determine likely benign markers among no-equivalence markers by identifying structural defects, prioritizing equivalent markers, identifying drugs or therapies related to equivalent-marker correspondence, and outputting an estimated response based on the equivalence levels.
Stated Advantages
Automatically prioritizing patient-specific marker values having equivalence to the reference marker.
Estimating a patient’s response to a plurality of cancer drugs or therapies based on determined equivalence level patient-specific marker values.
Determining patient-specific marker values that are likely benign from those having no equivalence to a reference marker value by applying structural rules to identify a structural defect.
Documented Applications
No documented applications found
Interested in licensing this patent?